NCT02046564View on ClinicalTrials.gov

Assess the Efficacy and Safety of ASC-01 in Patients With Major Depressive Disorder

PHASE3CompletedINTERVENTIONAL
Enrollment

412

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions
Major Depressive Disorder
Interventions
DRUG

ASC-01

DRUG

Placebo

Trial Locations (29)

Unknown

Everton Park

Melbourne

Chubu Region

Chugoku Region

Hokkaido Region

Kanto Region

Kinki Region

Kyushu Region

Tohoku Region

Ipoh

Johor Bahru

Kuala Lumpur

Kuching

Busan

Chungcheongnam-do

Deagu

Gangwon-do

Gwangju

Gyeonggi-do

Incheon

Jeollabuk-do

Seoul

Chiayi City

Kaohsiung City

Keelung

Taichung

Tainan City

Taipei

Taoyuan District

Sponsors
All Listed Sponsors
lead

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY

NCT02046564 - Assess the Efficacy and Safety of ASC-01 in Patients With Major Depressive Disorder | Biotech Hunter | Biotech Hunter